Economic Burden of Palmoplantar Pustulosis in Sweden: A Population-based Register Study
DOI:
https://doi.org/10.2340/actadv.v103.4501Keywords:
palmoplantar pustulosis, healthcare resource use, economic burden, healthcare register, population-based, epidemiologyAbstract
The aim of this study was to estimate the economic burden of palmoplantar pustulosis, a chronic relapsing skin condition commonly occurring in combination with psoriasis vulgaris. Using data from the Swedish National Patient Register and Swedish Prescribed Drug Register for 2015, the study estimated all-cause and palmoplantar pustulosis-specific healthcare resource use (inpatient stays, physician visits and drug use) for 14,715 patients with palmoplantar pustulosis, and compared these both with matched controls from the general population and with patients with psoriasis vulgaris (without palmoplantar pustulosis). Mean annual direct costs for a patient with palmoplantar pustulosis was higher compared with costs for the general population (3,000 vs 1,700 Euro, p < 0.001). Compared with psoriasis vulgaris, more patients with palmoplantar pustulosis had inpatient stays, but fewer had physician visits and psoriasis-related drugs; the overall costs were similar. Only a small fraction of the costs of physician visits and inpatient stays for patients with palmoplantar pustulosis were attributable to specific palmoplantar pustulosis problems, indicating a clear comorbidity burden in palmoplantar pustulosis.
Downloads
References
Noe MH, Wan MT, Mostaghimi A, Gelfand JM, Agnihothri R, Armstrong AW, et al. Evaluation of a case series of patients with palmoplantar pustulosis in the United States. JAMA Dermatol 2022; 158: 68-72.
https://doi.org/10.1001/jamadermatol.2021.4635 DOI: https://doi.org/10.1001/jamadermatol.2021.4635
Olazagasti JM, Ma JE, Wetter DA. Clinical features, etiologic factors, associated disorders, and treatment of palmoplantar pustulosis: the Mayo Clinic experience, 1996-2013. Mayo Clin Proc 2017; 92: 1351-1358.
https://doi.org/10.1016/j.mayocp.2017.05.029 DOI: https://doi.org/10.1016/j.mayocp.2017.05.029
Brunasso AMG, Massone C. Recent advances in palmoplantar pustulosis. Fac Rev 2021; 10: 62.
https://doi.org/10.12703/r/10-62 DOI: https://doi.org/10.12703/r/10-62
Andersen YMF, Augustin M, Petersen J, Hagenstrom K, Mallbris L, Burge R, et al. Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis. Br J Dermatol 2019; 181: 976-982.
https://doi.org/10.1111/bjd.17832 DOI: https://doi.org/10.1111/bjd.17832
Brunasso AM, Puntoni M, Aberer W, Delfino C, Fancelli L, Massone C. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol 2013; 168: 1243-1251.
https://doi.org/10.1111/bjd.12223 DOI: https://doi.org/10.1111/bjd.12223
Lee JY, Kang S, Park JS, Jo SJ. Prevalence of psoriasis in Korea: a population-based epidemiological study using the Korean National Health Insurance database. Ann Dermatol 2017; 29: 761-767.
https://doi.org/10.5021/ad.2017.29.6.761 DOI: https://doi.org/10.5021/ad.2017.29.6.761
Schäfer I, Rustenbach SJ, Radtke M, Augustin J, Glaeske G, Augustin M. Epidemiologie der Psoriasis in Deutschland - Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung. Gesundheitswesen 2011; 73: 308-313.
https://doi.org/10.1055/s-0030-1252022 DOI: https://doi.org/10.1055/s-0030-1252022
Na SJ, Jo SJ, Youn JI. Clinical study on psoriasis patients for past 30 years (1982-2012) in Seoul National University Hospital Psoriasis Clinic. J Dermatol 2013; 40: 731-735.
https://doi.org/10.1111/1346-8138.12224 DOI: https://doi.org/10.1111/1346-8138.12224
Yan D, Afifi L, Jeon C, Cordoro KM, Liao W. A cross-sectional study of the distribution of psoriasis subtypes in different ethno-racial groups. Dermatol Online J 2018; 24: 13030.
https://doi.org/10.5070/D3247040909 DOI: https://doi.org/10.5070/D3247040909
Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review. Expert Rev Clin Immunol 2020; 16: 253-266.
https://doi.org/10.1080/1744666X.2019.1708194 DOI: https://doi.org/10.1080/1744666X.2019.1708194
Hanna ML, Singer D, Valdecantos WC. Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States. Curr Med Res Opin 2021; 37: 735-742.
https://doi.org/10.1080/03007995.2021.1894108 DOI: https://doi.org/10.1080/03007995.2021.1894108
Becher G, Jamieson L, Leman J. Palmoplantar pustulosis - a retrospective review of comorbid conditions. J Eur Acad Dermatol Venereol 2015; 29: 1854-1856.
https://doi.org/10.1111/jdv.12545 DOI: https://doi.org/10.1111/jdv.12545
Misiak-Galazka M, Wolska H, Galazka A, Kwiek B, Rudnicka L. General characteristics and comorbidities in patients with palmoplantar pustulosis. Acta Dermatovenerol Croat 2018; 26: 109-118.
Trattner H, Bluml S, Steiner I, Plut U, Radakovic S, Tanew A. Quality of life and comorbidities in palmoplantar pustulosis - a cross-sectional study on 102 patients. J Eur Acad Dermatol Venereol 2017; 31: 1681-1685.
https://doi.org/10.1111/jdv.14187 DOI: https://doi.org/10.1111/jdv.14187
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450.
https://doi.org/10.1186/1471-2458-11-450 DOI: https://doi.org/10.1186/1471-2458-11-450
Löfvendahl S, Norlin JM, Schmitt-Egenolf M. Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study. Br J Dermatol 2021; 185: 945-951.
https://doi.org/10.1111/bjd.20087 DOI: https://doi.org/10.1111/bjd.20087
Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaëlsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 2016; 31: 125-136.
https://doi.org/10.1007/s10654-016-0117-y DOI: https://doi.org/10.1007/s10654-016-0117-y
National Board of Health and Welfare. [Instructions for NordDRG-Swedish version 2015] (in Swedish) (personal communication).
Swedish Association of Local Authorities and Regions. [Reference weights for inpatient and outpatient groups, NordDRG, 2015] (in Swedish). Available from https://skr.se/skr/halsasjukvard/ekonomiavgifter/kostnadperpatientkpp.1076.html.
Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-735.
https://doi.org/10.1002/pds.1294 DOI: https://doi.org/10.1002/pds.1294
Miyazaki C, Sruamsiri R, Mahlich J, Jung W. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: a claims database study. PLoS One 2020; 15: e0232738.
https://doi.org/10.1371/journal.pone.0232738 DOI: https://doi.org/10.1371/journal.pone.0232738
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Sofia Löfvendahl, Jenny M. Norlin, Marcus Schmitt-Egenolf
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
